Literature DB >> 33777029

Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses.

Aurélien Azam1,2, Sergio Mallart3, Stephane Illiano4, Olivier Duclos3, Catherine Prades1, Bernard Maillère2.   

Abstract

Non-natural modifications are widely introduced into peptides to improve their therapeutic efficacy, but their impact on immunogenicity remains largely unknown. As the CD4 T-cell response is a key factor in triggering immunogenicity, we investigated the effect of introducing D-amino acids (Daa), amino isobutyric acid (Aib), N-methylation, Cα-methylation, reduced amide, and peptoid bonds into an immunoprevalent T-cell epitope on binding to a set of HLA-DR molecules, recognition, and priming of human T cells. Modifications are differentially accepted at multiple positions, but are all tolerated in the flanking regions. Introduction of Aib and Daa in the binding core had the most deleterious effect on binding to HLA-DR molecules and T-cell activation. Their introduction at the positions close to the P1 anchor residue abolished T-cell priming, suggesting they might be sufficient to dampen peptide immunogenicity. Other modifications led to variable effects on binding to HLA-DR molecules and T-cell reactivity, but none exhibited an increased ability to stimulate T cells. Altogether, non-natural modifications appear generally to diminish binding to HLA-DR molecules and hence T-cell stimulation. These data might guide the design of therapeutic peptides to make them less immunogenic.
Copyright © 2021 Azam, Mallart, Illiano, Duclos, Prades and Maillère.

Entities:  

Keywords:  CD4 T-cell response; HLA class II molecules; T-cell epitope; immunogenicity; non-natural amino acids

Year:  2021        PMID: 33777029      PMCID: PMC7991740          DOI: 10.3389/fimmu.2021.637963

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  47 in total

1.  HLA-DR restricted peptide candidates for bee venom immunotherapy.

Authors:  C Texier; S Pouvelle; M Busson; M Hervé; D Charron; A Ménez; B Maillère
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

2.  Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1.

Authors:  Zarixia Zavala-Ruiz; Eric J Sundberg; Jennifer D Stone; Daniel B DeOliveira; Iat C Chan; Jennifer Svendsen; Roy A Mariuzza; Lawrence J Stern
Journal:  J Biol Chem       Date:  2003-09-01       Impact factor: 5.157

Review 3.  Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization.

Authors:  Luca Gentilucci; Rossella De Marco; Lucia Cerisoli
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

4.  Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude.

Authors:  James J Moon; H Hamlet Chu; Marion Pepper; Stephen J McSorley; Stephen C Jameson; Ross M Kedl; Marc K Jenkins
Journal:  Immunity       Date:  2007-08-16       Impact factor: 31.745

5.  Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively.

Authors:  Florence A Castelli; Diane Houitte; Gaetan Munier; Natacha Szely; Alain Lecoq; Jean-Paul Briand; Sylviane Muller; Bernard Maillere
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

Review 6.  Peptides as therapeutics with enhanced bioactivity.

Authors:  D Goodwin; P Simerska; I Toth
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

7.  Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands.

Authors:  K W Marshall; A F Liu; J Canales; B Perahia; B Jorgensen; R D Gantzos; B Aguilar; B Devaux; J B Rothbard
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

8.  Improved detection of human antibodies to a Plasmodium antigen using a peptide modified with Aib residues.

Authors:  M Bossus; L BenMohamed; A Londono; B Barbier; A Tartar; P Druilhe; H Gras-Masse; L Mohammed
Journal:  J Pept Sci       Date:  1997 Jan-Feb       Impact factor: 1.905

9.  Enhancing peptide antigenicity by helix stabilization.

Authors:  R Gurunath; T K Beena; P R Adiga; P Balaram
Journal:  FEBS Lett       Date:  1995-03-20       Impact factor: 4.124

10.  Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity.

Authors:  Jens Hennecke; Don C Wiley
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

View more
  1 in total

1.  Differential T cell immune responses to deamidated adeno-associated virus vector.

Authors:  So Jin Bing; Sune Justesen; Wells W Wu; Abdul Mohin Sajib; Stephanee Warrington; Alan Baer; Stephan Thorgrimsen; Rong-Fong Shen; Ronit Mazor
Journal:  Mol Ther Methods Clin Dev       Date:  2022-01-18       Impact factor: 6.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.